Markj Foley News Today

Truist Financial reissued their buy rating on shares of Glaukos (NYSE:GKOS – Free Report) in a research report released on Thursday morning, Benzinga reports. Truist Financial currently has a $125.00 price target on the medical instruments supplier’s stock, up from their previous price target of $120.00. A number of other research firms also recently commented […]

Glaukos Co. (NYSE:GKOS – Get Free Report)’s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as $102.60 and last traded at $101.81, with a volume of 32614 shares traded. The stock had previously closed at $101.10. Analyst Ratings Changes A number of analysts have recently commented […]

Shares of Glaukos Co. (NYSE:GKOS – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective […]

Robust Sales Drive 40% Quarterly and 77% Annual Revenue Increases

28.02.2024 - Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update. Financial Highlights Total revenue for the fourth quarter 2023 was $69.8 ...

- CMS streamlines reimbursement for DAXXIFY with assignment of permanent J-code - - Peer-reviewed publication of DAXXIFY pivotal data in therapeutics reinforces the products long duration of effect...

- CMS streamlines reimbursement for DAXXIFY with assignment of permanent J-code -- Peer-reviewed publication of DAXXIFY pivotal data in therapeutics reinforces the products long duration of effect and favorable safety profile -NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (RVNC) today announced that...

Revance Therapeutics, Inc. , today announced that the company will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference, taking place February 7-8, 2024, in New...

– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023...

– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%.– Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million.– Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%.– In August, DAXXIFY was approved by the FDA for the treatment of cervical dy...